Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 11 |
List of Tables | 11 | 1 |
List of Figures | 12 | 1 |
Introduction | 13 | 1 |
Global Markets Direct Report Coverage | 13 | 1 |
Hypercholesterolemia Overview | 14 | 1 |
Therapeutics Development | 15 | 2 |
Pipeline Products for Hypercholesterolemia Overview | 15 | 1 |
Pipeline Products for Hypercholesterolemia Comparative Analysis | 16 | 1 |
Hypercholesterolemia Therapeutics under Development by Companies | 17 | 3 |
Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
Hypercholesterolemia Pipeline Products Glance | 21 | 4 |
Late Stage Products | 21 | 1 |
Clinical Stage Products | 22 | 1 |
Early Stage Products | 23 | 1 |
Unknown Stage Products | 24 | 1 |
Hypercholesterolemia Products under Development by Companies | 25 | 4 |
Hypercholesterolemia Products under Investigation by Universities/Institutes | 29 | 1 |
Hypercholesterolemia Companies Involved in Therapeutics Development | 30 | 37 |
3SBio Inc | 30 | 1 |
AFFiRiS AG | 31 | 1 |
Akcea Therapeutics Inc | 32 | 1 |
Alvogen Korea Co Ltd | 33 | 1 |
ARMO Biosciences Inc | 34 | 1 |
AstraZeneca Plc | 35 | 1 |
BioLingus AG | 36 | 1 |
Catabasis Pharmaceuticals Inc | 37 | 1 |
Chong Kun Dang Pharmaceutical Corp | 38 | 1 |
CymaBay Therapeutics Inc | 39 | 1 |
Daewon Pharm Co Ltd | 40 | 1 |
Dicerna Pharmaceuticals Inc | 41 | 1 |
Dybly AG | 42 | 1 |
Esperion Therapeutics Inc | 43 | 1 |
Gemphire Therapeutics Inc | 44 | 1 |
Golden Biotechnology Corp | 45 | 1 |
Hanmi Pharmaceuticals Co Ltd | 46 | 1 |
Immune Response BioPharma Inc | 47 | 1 |
Johnson &Johnson | 48 | 1 |
Kadmon Corp LLC | 49 | 1 |
Kyorin Pharmaceutical Co Ltd | 50 | 1 |
Leading BioSciences Inc | 51 | 1 |
LipimetiX Development Inc | 52 | 1 |
Lotus Pharmaceutical Co Ltd | 53 | 1 |
Merck &Co Inc | 54 | 1 |
Pfizer Inc | 55 | 1 |
Planet Biotechnology Inc | 56 | 1 |
Progenra Inc | 57 | 1 |
Regeneron Pharmaceuticals Inc | 58 | 1 |
RegenxBio Inc | 59 | 1 |
Serometrix LLC | 60 | 1 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | 61 | 1 |
Solvotrin Therapeutics Ltd | 62 | 1 |
The Medicines Company | 63 | 1 |
Thetis Pharmaceuticals LLC | 64 | 1 |
Viking Therapeutics Inc | 65 | 1 |
Zhejiang Hisun Pharmaceutical Co Ltd | 66 | 1 |
Hypercholesterolemia Therapeutics Assessment | 67 | 12 |
Assessment by Monotherapy Products | 67 | 1 |
Assessment by Combination Products | 68 | 1 |
Assessment by Target | 69 | 3 |
Assessment by Mechanism of Action | 72 | 3 |
Assessment by Route of Administration | 75 | 2 |
Assessment by Molecule Type | 77 | 2 |
Drug Profiles | 79 | 108 |
(aspirin + lisinopril + lovastatin) Drug Profile | 79 | 1 |
(atorvastatin calcium + ezetimibe) Drug Profile | 80 | 1 |
(atorvastatin calcium + ezetimibe) Drug Profile | 81 | 1 |
(atorvastatin calcium + TP-452) Drug Profile | 82 | 1 |
(bempedoic acid + ezetimibe) Drug Profile | 83 | 1 |
(candesartan cilexetil + rosuvastatin calcium) Drug Profile | 84 | 1 |
(ezetimibe + rosuvastatin calcium) Drug Profile | 85 | 1 |
AEM-28 Drug Profile | 86 | 2 |
AEM-2802 Drug Profile | 88 | 1 |
AEM-2814 Drug Profile | 89 | 1 |
alirocumab Drug Profile | 90 | 11 |
AM-0010 Drug Profile | 101 | 3 |
anacetrapib Drug Profile | 104 | 2 |
Antibodies for Metabolic Disorders Drug Profile | 106 | 1 |
Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 107 | 1 |
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia Drug Profile | 108 | 1 |
antroquinonol Drug Profile | 109 | 2 |
ATH-04 Drug Profile | 111 | 1 |
ATH-06 Drug Profile | 112 | 1 |
bempedoic acid Drug Profile | 113 | 10 |
BSN-272 Drug Profile | 123 | 1 |
CAT-2000 Series Drug Profile | 124 | 1 |
CAT-2003 Drug Profile | 125 | 3 |
colestilan chloride Drug Profile | 128 | 1 |
D-4F Drug Profile | 129 | 1 |
DCRPCSK-9 Drug Profile | 130 | 1 |
Drugs for Hypercholesterolemia Drug Profile | 131 | 1 |
Drugs to Inhibit Sortilin for Hypercholesterolemia Drug Profile | 132 | 1 |
DW-0929 Drug Profile | 133 | 1 |
DW-3102 Drug Profile | 134 | 1 |
DYB-186 Drug Profile | 135 | 1 |
EP-80317 Drug Profile | 136 | 1 |
evinacumab Drug Profile | 137 | 2 |
gemcabene calcium Drug Profile | 139 | 2 |
Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 141 | 1 |
HCP-1305 Drug Profile | 142 | 1 |
HGP-0816 Drug Profile | 143 | 1 |
HS-25 Drug Profile | 144 | 1 |
inclisiran Drug Profile | 145 | 4 |
IONIS-ANGPTL3LRx Drug Profile | 149 | 1 |
IR-1002 Drug Profile | 150 | 1 |
KD-026 Drug Profile | 151 | 1 |
MBX-8025 Drug Profile | 152 | 3 |
MGL-3196 Drug Profile | 155 | 2 |
MGL-3745 Drug Profile | 157 | 1 |
MN-002 Drug Profile | 158 | 1 |
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 159 | 1 |
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 160 | 1 |
PF-06446846 Drug Profile | 161 | 1 |
Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 162 | 1 |
RGX-501 Drug Profile | 163 | 2 |
rosuvastatin calcium Drug Profile | 165 | 1 |
Small Molecule for Hypercholesterolemia Drug Profile | 166 | 1 |
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia Drug Profile | 167 | 1 |
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 168 | 1 |
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 169 | 1 |
Small Molecules to Inhibit IDOL for Hypercholesterolemia Drug Profile | 170 | 1 |
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 171 | 1 |
Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Drug Profile | 172 | 2 |
ST-0702 Drug Profile | 174 | 1 |
SX-PCK9 Drug Profile | 175 | 1 |
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia Drug Profile | 176 | 1 |
Vaccine to Target PCSK9 for Hypercholesterolemia Drug Profile | 177 | 1 |
VK-2809 Drug Profile | 178 | 3 |
volanesorsen sodium Drug Profile | 181 | 6 |
Hypercholesterolemia Dormant Projects | 187 | 7 |
Hypercholesterolemia Discontinued Products | 194 | 2 |
Hypercholesterolemia Product Development Milestones | 196 | 17 |
Featured News &Press Releases | 196 | 1 |
Nov 15, 2016: The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si) | 196 | 1 |
Nov 15, 2016: Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016 | 197 | 1 |
Nov 11, 2016: Regeneron and Sanofi to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016 | 198 | 2 |
Oct 18, 2016: The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si | 200 | 1 |
Oct 13, 2016: Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose | 201 | 2 |
Oct 05, 2016: The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si | 203 | 1 |
Oct 04, 2016: Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease | 204 | 1 |
Sep 26, 2016: Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial Investigating Gemcabene in Homozygous Familial Hypercholesterolemia | 205 | 1 |
Sep 19, 2016: Gemphire Therapeutics Announces Publication of Phase 2 Data for Gemcabene in the Journal of Clinical Lipidology | 205 | 1 |
Sep 15, 2016: Akcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome | 206 | 1 |
Aug 30, 2016: The Medicines Company Provides Update on PCSK9si (PCSK9 synthesis inhibitor) | 207 | 1 |
Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016 | 208 | 1 |
Aug 04, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Update | 209 | 1 |
Jul 28, 2016: Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy | 210 | 1 |
Jul 05, 2016: Regeneron and Sanofi Announce Approval of Praluent (alirocumab) for the Treatment of Hypercholesterolemia in Japan | 211 | 2 |
Appendix | 213 | 2 |
Methodology | 213 | 1 |
Coverage | 213 | 1 |
Secondary Research | 213 | 1 |
Primary Research | 213 | 1 |
Expert Panel Validation | 213 | 1 |
Contact Us | 213 | 1 |
Disclaimer | 214 | 1 |